Completed PHASE4 INTERVENTIONAL 3-arm
NCT05887804
Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial
Sponsor: Indonesia University
Interventions
Triamcinolone Acetonide (TA) umbilical cord-derived mesenchymal stem cells (UC-MSC) umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)
Updated 3 times since 2023 Last updated: Jun 5, 2023 Started: Oct 1, 2021 Primary completion: Jun 9, 2022 Completion: Jun 9, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Keloid and Stem Cell, this trial is completed. The trial is conducted by Indonesia University and has accumulated 3 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE4
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Indonesia University
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Data source: Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
For direct contact, visit the study record on ClinicalTrials.gov .